Search Results - "Travert, Camille"

Immune Oncology Biomarkers in Lung Cancer: an Overview by Travert, Camille, Barlesi, Fabrice, Greillier, Laurent, Tomasini, Pascale

“…Purpose of Review Lung cancer is still the first cause of cancer-related deaths worldwide. The development of immune checkpoint inhibitors (ICI) has…”
Get full text

Nivolumab plus ipilimumab in malignant pleural mesothelioma by Travert, Camille, Tomasini, Pascale, Greillier, Laurent

“…Unresectable pleural mesothelioma is a poor prognosis disease. Improvement in overall survival (OS) has been shown with PEMETREXED combined with CISPLATIN…”
Get full text

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer? by Travert, Camille, Tomasini, Pascale, Barlesi, Fabrice

Get full text

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer by Travert, Camille, Tomasini, Pascale, Jeanson, Arnaud, Greillier, Laurent, Barlesi, Fabrice

Get full text

Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance by Mancini, Maicol, Thomas, Quentin-Dominique, Bourdel, Sylvia, Papon, Laura, Bousquet, Emilie, Jalta, Prisca, La Monica, Silvia, Travert, Camille, Alfieri, Roberta, Quantin, Xavier, Cañamero, Marta, Maraver, Antonio

“…Despite the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) to treat advanced lung cancer harboring EGFR-activating…”
Get full text

Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma by Nokin, Marie-Julie, Darbo, Elodie, Travert, Camille, Drogat, Benjamin, Lacouture, Aurélie, San José, Sonia, Cabrera, Nuria, Turcq, Béatrice, Prouzet-Mauleon, Valérie, Falcone, Mattia, Villanueva, Alberto, Wang, Haiyun, Herfs, Michael, Mosteiro, Miguel, Jänne, Pasi A, Pujol, Jean-Louis, Maraver, Antonio, Barbacid, Mariano, Nadal, Ernest, Santamaría, David, Ambrogio, Chiara

“…Platinum-based chemotherapy in combination with immune-checkpoint inhibitors is the current standard of care for patients with advanced lung adenocarcinoma…”
Get full text